ALK and non-small cell lung carcinoma: In the ALUR trial (NCT02604342), a randomized, multicenter, open-label, phase 3 study, researchers compared the efficacy of alectinib to chemotherapy in patients with advanced or metastatic ALK+ NSCLC.